MedTrace Logo

Human Albumin Treatment in Adult Septic Shock. A Study Evaluating Immune Response and Organ Failure.

NCT05645887 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-07-31

No results posted yet for this study

Summary

The goal of this phase 2, multicenter, randomized, controlled study is to evaluate the effect of albumin treatment on B cell and other immune cell gene exptression in adults with septic shock.

Conditions

  • Septic Shock

Interventions

DRUG

Human albumin

Human albumin from day 0 to 7 if serum albumin concentrations \<35g/l.

OTHER

Saline solution

Saline solution from day 0 to day 7.

Sponsors & Collaborators

  • Albimmune SL

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-29
Primary Completion
2024-05-23
Completion
2024-05-23

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05645887 on ClinicalTrials.gov